Repros Therapeutics Inc.(R) Announces Proposed Public Offering of Common Stock
THE WOODLANDS, Texas, June 17, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics
Inc. (Nasdaq:RPRX) today announced that it has commenced an underwritten
public offering of up to 3,000,000 shares of its common stock. All of the
shares in the offering are to be sold by Repros Therapeutics Inc.
BofA Merrill Lynch is acting as the sole book-running manager for the offering
and Lazard Capital Markets LLC, Ladenburg Thalmann & Co. Inc. and Ascendiant
Capital Markets, LLC are acting as co-managers in the offering. Repros
Therapeutics intends to grant the underwriters a 30-day option to purchase up
to an additional 15% of the number of shares sold. The offering is subject to
market conditions which may delay or prevent the offering from being
completed, or impact the actual size or terms of the offering.
The securities described above are being offered by Repros Therapeutics
pursuant to an existing shelf registration statement that Repros Therapeutics
filed with the Securities and Exchange Commission ("SEC").
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy any securities nor shall there be any sale of these
securities in any state in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
The offering may be made only by means of a prospectus supplement and
accompanying base prospectuses meeting the requirements of Section 10 of the
Securities Act of 1933, as amended.A preliminary prospectus supplement
related to the offering is expected to be filed with the SEC and, if and when
filed, will be available, free of charge, on the SEC's website located at
www.sec.gov. Alternatively, copies of the preliminary prospectus supplement
and the accompanying prospectus relating to this offering may be obtained from
the offices of: BofA Merrill Lynch, 222 Broadway, New York, New York 10038,
Attention: Prospectus Department or by emailing
email@example.com.The final terms of the offering will be
disclosed in a final prospectus supplement filed with the SEC.Before you
invest, you should read the prospectus, the related prospectus supplement and
the documents incorporated by reference therein with respect to the offering
and any other document Repros Therapeutics has filed with the SEC for more
complete information about Repros Therapeutics and the offering.
About Repros Therapeutics Inc.
Repros Therapeutics focuses on the development of small molecule drugs for
major unmet medical needs that treat male and female reproductive
Statements contained in this press release about Repros Therapeutics that are
not purely historical, and all other statements that are not purely
historical, may be deemed to be forward-looking statements for purposes of the
safe harbor provisions under The Private Securities Litigation Reform Act of
1995. The words "anticipates," "believes," "estimates," "expects," "intends,"
"may," "plans," "projects," "will," "would" and similar expression are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. These
forward-looking statements involve known and unknown risks and uncertainties
that may cause Repros Therapeutics' actual results, levels of activity,
performance or achievements to be materially different from those expressed or
implied by the forward-looking statements Repros Therapeutics makes. Important
factors that may cause or contribute to such differences include whether or
not Repros Therapeutics will offer the shares or consummate the offering at
all or on the anticipated terms of the offering, fluctuations in Repros
Therapeutics' stock price, the anticipated use of the proceeds of the
offering, Repros Therapeutics' ability to satisfy customary closing conditions
related to the proposed offering, and such other factors as are set forth in
the risk factors detailed from time to time in the Repros Therapeutics'
periodic reports and registration statements filed with the SEC including,
without limitation, the risk factors detailed in the Repros Therapeutics'
Annual Report on Form 10-K filed in March, 2013, and the preliminary
prospectus supplement Repros Therapeutics expects to file with the SEC under
the heading "Risk Factors." You should not place undue reliance on these
forward-looking statements. In addition, any forward-looking statements
represent Repros Therapeutics' views only as of today and should not be relied
upon as representing Repros Therapeutics' views as of any subsequent date.
Repros Therapeutics disclaims any obligation to update any forward-looking
CONTACT: The Trout Group
Press spacebar to pause and continue. Press esc to stop.